A Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Elective Surgery Patients

A Multi-Center, Randomized, Open-Label, Positive-Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction and Maintenance of General Anesthesia in Elective Surgery Patients.

This is a multi-center, randomized, open-label, positive-controlled (propofol) phase II clinical trial. The study plans to enroll approximately 46 eligible subjects. Among them, 40 subjects will be randomly assigned to HSK3486 treatment group (30 cases) and propofol control group (10 cases) in a ratio of 3:1. The subjects will be enrolled competitively at all study sites. Upon enrollment of the 40 subjects, 6 more subjects will be enrolled by West China Hospital of Sichuan University. These 6 subjects will not be randomized, but will directly enter into propofol induction + HSK3486 maintenance group for study.

Study Overview

• Status: Completed
• Conditions: Induction and Maintenance of General Anesthesia
• Intervention / Treatment: Drug: HSK3486; Drug: Propofol; Drug: Propofol HSK3486

• Study Type: Interventional
• Enrollment (Actual): 46
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Peking, China
    • Peking University First Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Inpatients requiring tracheal intubation under general anesthesia and a non-emergent, non-cardiothoracic, non-extracerebral, and non-nasal endoscopic elective surgery for an estimated duration of about 1-6 h, with an bleeding volume of ≤ 1000 mL
2. Aged ≥ 18 and ≤ 65 years old, regardless of gender;
3. American Society of Anesthesiologists (ASA) Class I-III;
4. Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2;

5. The vital signs during the screening period meet the following criteria:

   • Respiratory rate ≥ 10 and ≤ 24 breaths/min;
   • Blood oxygen saturation (SpO2) ≥ 95% when inhaling;
   • Systolic blood pressure (SBP) ≥ 90 mmHg and ≤ 160 mmHg;
   • Diastolic blood pressure (DBP) ≥ 60 mmHg and ≤ 100 mmHg;
   • Heart rate ≥ 55 beats/min and ≤ 100 beats/min;

6. The laboratory parameters measured at screening period reach the following criteria:

   • Neutrophil count ≥ 1.5 × 109/L;
   • Platelet count ≥ 80 × 109/L;
   • Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days);
   • ALT and AST ≤ 3.0 × upper limit of normal (ULN);
   • Total bilirubin ≤ 1.5 × ULN;
   • Serum creatinine ≤ 1.5 × ULN.
7. Subjects who understand the procedures and methods of this study, and are willing to complete the trial in strict accordance with clinical trial protocol and sign the informed consent.

Exclusion Criteria:

1. Patients with contraindications to general anesthesia or previous history of anesthesia accidents;
2. Known hypersensitivity to excipients and ingredients found in propofol injection and HSK3486 injectable emulsion (soybean oil, glycerin, triglycerides, egg lecithin, sodium oleate, and sodium hydroxide), benzodiazepines, opioids, rocuronium bromide, and sugammadex sodium; cross-reactivity to halogenated anesthetics, jaundice or unexplained fever from previous use of halogenated anesthetics; contraindications to propofol;

3. Medical history or evidence of any of the following prior to screening, which may increase sedation/anesthesia risk:

   • History of cardiovascular disease: Uncontrolled hypertension or SBP > 160 mmHg and/or DBP > 100 mmHg despite antihypertensive treatment, severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction occurring in almost 6 months prior to screening, and history of tachycardia/bradycardia requiring medication, third-degree atrioventricular block or QTcF ≥ 450 ms (male) or ≥ 470 ms (female) (corrected using Fridericia's formula) during screening period.
   • Respiratory system disorders: Respiratory insufficiency, history of bronchospasm requiring treatment within 3 months prior to screening, acute respiratory tract infection with obvious symptoms such as fever, wheezing, or productive cough within 1 week prior to administration of the study drug;
   • History of craniocerebral disease: Patient with a history of craniocerebral injury, convulsions, epilepsy, intracranial hypertension, cerebral aneurysm, or cerebrovascular accident; history of schizophrenia, mania, chronic use of antipsychotics, or cognitive impairment.
   • Gastrointestinal disease history: Gastrointestinal retention, active hemorrhage, or circumstances that may lead to reflux and aspiration.
   • Diabetic patients with uncontrolled blood glucose (fasting blood glucose ≥ 11.1 mmol/L, and/or random blood glucose ≥ 13.6 mmol/L).
   • Patients with a history of uncontrolled and clinically significant liver, kidney, blood system, nervous system or metabolic system diseases judged by the investigator to be unsuitable for this trial.
   • History of alcohol abuse within 3 months prior to screening, where alcohol abuse refers to daily alcohol drinking > 2 units of alcohol (1 unit = 360 mL of beer or 45 mL of liquor with 40% alcohol or 150 mL of wine).
   • History of drug abuse within 3 months prior to screening.
   • Serious infection, trauma, or major surgery within 4 weeks prior to screening.

4. Any one of the following respiratory risks before/during screening:

   • Asthma history, and stridor.
   • Sleep apnea syndrome.
   • History of malignant hyperthermia or family history.
   • History of failed tracheal intubation.
   • Judged by the investigator to have difficult airway or judged as difficult tracheal intubation (modified Mallampati score III or IV);

5. Received any of the following drugs or therapies prior to screening:

   • Participated in other drug trials within 1 month prior to screening.
   • Using the drugs that may affect QT interval within 2 weeks prior to screening.
   • Using propofol, other sedatives/anesthetics, and/or opioid analgesics or compounds containing analgesics within 3 days prior to screening.
6. Women who are pregnant or breastfeeding; women of child-bearing potential or men who are unwilling to use contraception during the trial; Subjects who are planning pregnancy within 1 month after the completion of the trial (including male subjects);
7. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HSK3486; HSK3486 induction + maintenance group	Drug: HSK3486; The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
Active Comparator: Propofol; Propofol induction + maintenance group	Drug: Propofol; The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
Other: Propofol HSK3486; Propofol induction + HSK3486 maintenance group	Drug: Propofol HSK3486; The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Success rate of anesthesia maintenance	During the maintenance of anesthesia, the subject is not recovered and no remedial anesthetic is used	During maintenance of general anesthesia on day 1
Number of patients with adverse events	Safety endpoints	Pre-dose to 48 hours post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Success rate of anesthesia induction	During the induction of anesthesia, the subject achieves successful induction (i.e., MOAA/S ≤ 1) after administration of the study drug (up to 2 additional doses), and no remedial anesthetic is used.	During induction of general anesthesia on day 1
Success rate of anesthesia	The proportion of subjects who are successfully induced and successfully maintain anesthesia in all subjects.	During induction and maintenance of general anesthesia on day 1
Changes in Bispectral index	Bispectral index (BIS) is used to adjust the administration dose during anesthesia maintenance to maintain BIS at 40-60	During maintenance of general anesthesia on day 1
Time to successful induction of anesthesia	A period of time from the start of the first administration of the study drug to the first time when MOAA/S is ≤ 1.	Time to successful induction of anesthesia on day 1
Time to recovery from anesthesia	6.Record the time when MOAA/S = 5 is reached for the first time.	A period of time from discontinuation of the study drug to recovery after the end of surgery on day 1.
Time to respiratory recovery	Respiratory rate ≥ 8 breaths/min and the tidal volume ≥ 5 mL/kg.	A period of time from discontinuation of the study drug to respiratory recovery after the end of surgery on day 1.
Time to extubation		A period of time from discontinuation of the study drug to extubation after the end of surgery on day 1.
Time to leaving the operating room		A period of time from discontinuation of the study drug to leaving the operating room after the end of surgery on day 1.
Time to leaving postanesthesia care unit(PACU)		A period of time from discontinuation of the study drug to leaving PACU after the end of surgery on day 1.

Collaborators and Investigators

• Sponsor: Sichuan Haisco Pharmaceutical Group Co., Ltd

Study record dates

Study Major Dates

• Study Start (Actual): December 9, 2019
• Primary Completion (Actual): May 23, 2020
• Study Completion (Actual): June 22, 2020

Study Registration Dates

• First Submitted: July 31, 2019
• First Submitted That Met QC Criteria: August 5, 2019
• First Posted (Actual): August 7, 2019

Study Record Updates

• Last Update Posted (Actual): December 17, 2020
• Last Update Submitted That Met QC Criteria: December 16, 2020
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Central Nervous System Depressants; Anesthetics, Intravenous; Anesthetics, General; Anesthetics; Hypnotics and Sedatives; Propofol
• Other Study ID Numbers: HSK3486-204

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No